Skip to main content

Market Overview

ICYMI: Valeant, Overstock And Biotechs

Share:

In case you missed it, here are some of Benzinga's top stories from Monday, March 5, 2018.

A Valeant Bear Relents

Learn what finally convinced Deutsche Bank’s Gregg Gilbert to grant a buy rating to Valeant Pharmaceuticals Inc (NYSE: VRX) in Elizabeth Balboa’s “How Valeant Finally Won Over A Longtime Bear.”

Overstock Bull Sharpens His Horns Ahead Of ICO

Despite last week’s SEC scare, Overstock.com Inc (NASDAQ: OSTK) is still a hot stock with plenty of upside, according to D.A. Davidson. Get some background on this bull’s thesis in Wayne Duggan’s “Analyst Stays Bullish On Overstock's tZERO Coin Offering Despite Regulatory Risk.”

Related Link: Morgan Stanley Says Groupon's 16% Decline In 2018 Is 'Overdone'

Keep Your Eyes Peeled For These 7 Biotechs In March

From Regeneron Pharmaceuticals Inc (NASDAQ: REGN) to ImmunoGen, Inc (NASDAQ: IMGN), several biotechs are expected to release meaningful updates on their clinical programs this month. Shanthi Rexaline has the details.

Latest Ratings for GRPN

DateFirmActionFromTo
Mar 2021JP MorganUpgradesUnderweightNeutral
Mar 2021Credit SuisseMaintainsNeutral
Jan 2021Morgan StanleyMaintainsEqual-Weight

View More Analyst Ratings for GRPN
View the Latest Analyst Ratings

 

Related Articles (REGN + GRPN)

View Comments and Join the Discussion!

Posted-In: Analyst Color Biotech Cryptocurrency News Previews After-Hours Center Markets Analyst Ratings

Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
SPAC
Everything you need to know about the latest SPAC news.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com